Drug intelligence / Profile preview

P-680

Development stage: Preclinical
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Inhalation

Overview

P-680 is an investigational epithelial sodium channel (ENaC) blocker developed by Parion Sciences for the treatment of pulmonary diseases, particularly cystic fibrosis (CF). It works by inhibiting ENaC in airway epithelial cells to increase airway surface liquid volume, thereby improving mucociliary clearance and lung function in CF patients. In 2007, Parion Sciences licensed worldwide commercialization rights to Gilead Sciences to advance its development.

Targets

ENaC

Beyond the preview

Go deeper on P-680.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P-680.

Explore the full profile